DNA plasmids is the closest thing from a biological material to a chemical material, you can characterize down to specific nucleotide, or even chemical elements through PCRs and other analytical essays. And that's an area that Inovio has invested heavily into for several years.
So we’re confident that we can demonstrate comparability of products, whether it's made at Thermo Fisher, or Ology or else Richter-Helm or elsewhere.So we took this tact of bringing on a global consortium of manufacturers that can help us to manufacture up to 100s of millions of doses going forward. So that's we're not as big as Pfizer or even Moderna. So we had to think more creatively or that's the tact that we have taken and I think we've taken a great step forward in solving for this manufacturing challenge.
And I can tell you now that that's no longer a major challenge for us. And we will be bringing on additional manufacturer to this growing global consortium of manufacturers for plasmids, similarly to the devices, so we’re calculating to have about 1,000 handheld devices, one device to deliver about thousand doses in the field. Each device can deliver up to 5,000 or more doses and we’re putting in a high scale manufacturing lines to help us to do that starting 2021, the actual needle parts what we call the arrays are single use, so they have to match the number of doses. Again with the leverage of DoD funding that we announced in the summer, we’re able to put in automated manufacturing lines both here in the U.S. and eventually ex-U.S. to scale-up the array manufacturing.
Inovio Pharmaceuticals, Inc. (INO) President & CEO Joseph Kim Presents at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Transcript
Sep. 23, 2020 2:06 PM
